DOCSLIB.ORG

Cooperating Saves Lives Start Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cooperating Saves Lives Start Contents Annual Report 2019 Cooperating saves lives start contents Contents Foreword 1. The Eurotransplant community 2. Eurotransplant: donation, allocation, transplantation and waiting lists This document is optimized for Acrobat Reader for best viewing 3. Report of the Board and the central office experience. 4. Histocompatibility Testing Download Acrobat Reader 5. Reporting of non-resident transplants in Eurotransplant 6. Transplant programs and their delegates in 2019 A high resolution version of this document is also available. 7. Scientific output in 2019 Download high resolution pdf 8. Eurotransplant personnel related statistics 9. Abbreviated financial statements All rights reserved. No part of this publication may be reproduced, stored in a retrieval system List of abbreviations or transmitted, in any form or by any means, electronic, mechanical, photocopying or elsewise, without prior permission of Eurotransplant. For permissions, please contact: [email protected] start contents Foreword Dear reader, We are proud to offer you the 2019, digital edition of the International organ exchange Eurotransplant Annual Report. In this environmentally In 2019, 6981 organs from 2042 deceased donors were friendly, digital report you can easily browse via the used for transplantation for patients on the waiting top menu. Weblinks are added to facilitate in finding list of Eurotransplant. This decrease of the number of more specific information on relevant websites. The reported donors is 5,5% compared to 2018 (2159). report provides an overview of the key statistics on 21.5% of organs were exchanged cross-border between organ donation, allocation and transplantation in all the Eurotransplant member states. Thanks to this Eurotransplant countries. international exchange, a suitable donor organ could be You can also read in the report activities within found for many patients in the different Eurotransplant Eurotransplant that took place, decisions that were member states. This specifically applies to patients in made as well as the financial status. Comprehensive and specific groups such as children, patients with acute more detailed annual statistics are online available via organ failure (high urgency patients) as well as patients statistics.eurotransplant.org. with a complex medical background (highly immunized patients). For these specific patient groups the chance Together on a life saving mission of receiving a suitable organ in time is significantly All healthcare providers work together 24 hours a day higher, due to the cooperation within Eurotransplant. with the same common goal to ensure that the best possible match is made between available donor organs Towards a new Governance structure and patients on the transplant waiting list. In this After almost five years of discussion, adaptations and way, a growing number of patients have a healthy life preparations, the goal of the Eurotransplant Board and a better quality of life. The cooperation between has been achieved: a new Eurotransplant governance Eurotransplant and non Eurotransplant countries is structure came into effect in January 2020. of great value. Through cooperation, data exchange 2019 was dominated by the implementation of the new, and monitoring, we also make a joint contribution democratic structure that meets current standards, to transplant medicine. We would like to take this obligations and best practices in non-profit governance. opportunity to express our gratitude for the good Following the approval of the General Assembly and fruitful cooperation for the benefit of all patients in October 2019, the new structure consisting of a awaiting their life-saving organ transplants. Supervisory Board, Board of Management, a Council of start contents Foreword Administration and a Council of Medicine and Science, Loss of Prof. Dr. Xavier Rogiers came into effect shortly after. With this structure, the On November 20, 2019 Eurotransplant’s vice president national authorities, the national transplant societies and long-time board member Prof. Dr. Xavier Rogiers and the Eurotransplant transplant programs have input passed away. He will be sorely missed by all of us. Prof. in the policy and practice of Eurotransplant. Detailed Dr. Rogiers made invaluable contributions to setting information on the new governance structure can be quality standards in liver and intestinal transplantation found on the renewed Eurotransplant public website and allocation, developing the all-important data eurotransplant.org/about-eurotransplant/organization/ registry, and lately, having intense debate and negotiation on the new Eurotransplant governance Relocation Eurotransplant office structure. We will remember him as a Moving the Eurotransplant office to another location good friend, a wise advisor and a tireless supporter in Leiden played an important role in 2019. Due to of cooperation. the efforts of all our employees and the excellent preparations, the relocation was successfully completed We are looking forward to a continuation of our in December 2019 without interrupting the 24/7 good cooperation with all partners in our eight allocation process. member states. Dr. Peter Branger Serge Vogelaar, MD General Director Medical Director 1 2 3 4 5 6 7 8 9 start contents The 1 Eurotransplant community “ I am able to lead a normal life thanks to the transplant.” 1 2 3 4 5 6 7 8 9 start contents The Eurotransplant community The Eurotransplant community The Stichting Eurotransplant International Foundation 1.1 Mission • To further improve the results of transplantation is a non-profit international organization that facilitates through collection and evaluation of donor, recipient, allocation and cross border exchange of deceased donor Organ transplantation offers life-saving and quality- allocation, transplantation and follow-up data, organs for its members: Austria, Belgium, Croatia, of-life enhancing treatment options to patients with scientific research and to publish and present these Germany, Hungary, Luxembourg, the Netherlands and end-stage organ failure. Aiming to fulfill this potential, results; Slovenia. In this international collaborative framework, Eurotransplant was established and acts as a mediator • The promotion, support and coordination of organ the participants include all transplant hospitals, tissue between donor hospitals and transplant centers, for the donation and transplantation in the broadest sense typing laboratories and hospitals where organ donations benefit of such patients. of terms. take place. The Eurotransplant region is serving a As such, Eurotransplant manages the complex process total population of around 137 million people. The of achieving the best possible match between available More information on the Eurotransplant’s aims can be organizational structure is democratic, with a Board of donor organs and patients on the transplant waiting list. found on eurotransplant.org/about-eurotransplant/ Management, a Management Team, an Assembly, a Council, Eurotransplant acts transparently and in accordance with eurotransplants-aims eight Advisory Committees of which four organ specific the regulations and ethical principles of the European (kidney, liver/intestine, heart/lung, pancreas) and four Union. This means that Eurotransplant fully complies in charge of organ procurement, tissue typing, ethics and with the national legislation of the Member States. 1.2 Method of working finance as well as an Information Services Working Group The Eurotransplant Foundation is actively involved in (ISWG) and an Eurotransplant Registry Advisory Committee developing best practice recommendations and policies The allocation of organs is an information-intensive process (ERAC). With this structure, the national authorities in to further improve organ allocation and transplantation which depends on an effective and efficient information the member countries, the national transplant societies results, based on robust data collection and state-of-the- and communication system. Therefore Eurotransplant and the Eurotransplant transplant programs have input art scientific research. continuously develops and maintains information systems in the policy and practice of Eurotransplant International that are required to support this process. These systems Foundation. Information on the current organizational To achieve its mission Eurotransplant has set the following process the vast amount of information, support the structure can be found at eurotransplant.org/about- goals: analysis of processes, of allocation rules and of other eurotransplant/organization/ • To achieve an optimal use of available donor organs and information and transform this into effective information tissues; systems. It is an integrated automated system designed • To secure a transparent, objective and fair allocation to collect, store and share information pertinent to the system, in compliance with national rules, based upon services provided by Eurotransplant. medical and ethical criteria; • To support donor procurement to increase the supply of Eurotransplant adequately tests all procedures and systems donor organs and tissues; and maintains a quality system to assure this. 1 2 3 4 5 6 7 8 9 start contents The Eurotransplant community Eurotransplant is committed to protecting the privacy of individuals and ensuring the security of their personal health information. It has designed a privacy and security framework which enables an effective coordination of privacy and security policies. The
Load more

Recommended publications
  • The History of the First Kidney Transplantation
    165+3 14 mm "Service to society is the rent we pay for living on this planet" The History of the Joseph E. Murray, 1990 Nobel-laureate who performed the first long-term functioning kidney transplantation in the world First Kidney "The pioneers sacrificed their scientific life to convince the medical society that this will become sooner or later a successful procedure… – …it is a feeling – now I am Transplantation going to overdo - like taking part in creation...” András Németh, who performed the first – a European Overview Hungarian renal transplantation in 1962 E d i t e d b y : "Professor Langer contributes an outstanding “service” to the field by a detailed Robert Langer recording of the history of kidney transplantation as developed throughout Europe. The authoritative information is assembled country by country by a generation of transplant professionals who knew the work of their pioneer predecessors. The accounting as compiled by Professor Langer becomes an essential and exceptional reference document that conveys the “service to society” that kidney transplantation has provided for all mankind and that Dr. Murray urged be done.” Francis L. Delmonico, M.D. Professor of Surgery, Harvard Medical School, Massachusetts General Hospital Past President The Transplantation Society and the Organ Procurement Transplant Network (UNOS) Chair, WHO Task Force Organ and Tissue Donation and Transplantation The History of the First Kidney Transplantation – a European Overview European a – Transplantation Kidney First the of History The ISBN 978-963-331-476-0 Robert Langer 9 789633 314760 The History of the First Kidney Transplantation – a European Overview Edited by: Robert Langer SemmelweisPublishers www.semmelweiskiado.hu Budapest, 2019 © Semmelweis Press and Multimedia Studio Budapest, 2019 eISBN 978-963-331-473-9 All rights reserved.
    [Show full text]
  • Newsletteralumni News of the Newyork-Presbyterian Hospital/Columbia University Department of Surgery Volume 13, Number 1 Summer 2010
    NEWSLETTERAlumni News of the NewYork-Presbyterian Hospital/Columbia University Department of Surgery Volume 13, Number 1 Summer 2010 CUMC 2007-2009 Transplant Activity Profile* Activity Kidney Liver Heart Lung Pancreas Baseline list at year start 694 274 174 136 24 Deceased donor transplant 123 124 93 57 11 Living donor transplant 138 17 — 0 — Transplant rate from list 33% 50% 51% 57% 35% Mortality rate while on list 9% 9% 9% 15% 0% New listings 411 217 144 68 23 Wait list at year finish 735 305 204 53 36 2007-June 2008 Percent 1-Year Survival No % No % No % No % No % Adult grafts 610 91 279 86 169 84 123 89 6 100 Adult patients 517 96 262 88 159 84 116 91 5 100 Pediatric grafts 13 100 38 86 51 91 3 100 0 — Pediatric patients 11 100 34 97 47 90 2 100 0 — Summary Data Total 2009 living donor transplants 155 (89% Kidney) Total 2009 deceased donor transplants 408 (30% Kidney, 30% Liver) 2007-June 2008 adult 1-year patient survival range 84% Heart to 100% Pancreas 2007-June 2008 pediatric 1-year patient survival range 90% Heart to 100% Kidney or lung *Health Resource and Service Administration’s Scientific Registry of Transplant Recipients (SRTR) Ed Note. The figure shows the US waiting list for whole organs which will only be partially fulfilled by some 8,000 deceased donors, along with 6,600 living donors, who will provide 28,000 to 29,000 organs in 2010. The Medical Center’s role in this process is summarized in the table, and the articles that follow my note expand on this incredible short fall and its potential solutions.
    [Show full text]
  • Analysis of the Trend Over Time of High-Urgency Liver Transplantation Requests in Italy in the 4-Year Period 2014-2017
    Analysis of the Trend Over Time of High-Urgency Liver Transplantation Requests in Italy in the 4-Year Period 2014-2017 S. Trapani*, F. Puoti, V. Morabito, D. Peritore, P. Fiaschetti, A. Oliveti, M. Caprio, L. Masiero, L. Rizzato, L. Lombardini, A. Nanni Costa, and M. Cardillo Italian National Transplant Center, Italian Institute of Health, Rome, Italy ABSTRACT Background. The national protocol for the handling of high-urgency (HU) liver organ procurement for transplant is administered by the Italian National Transplant Center. In recent years, we have witnessed a change in requests to access the program. We have therefore evaluated their temporal trend, the need to change the access criteria, the percentage of transplants performed, the time of request satisfaction, and the follow-up. Methods. We analyzed all the liver requests for the HU program received during the 4-year period of 2014 to 2017 for adult recipients (18 years of age): all the variables linked to the recipient or to the donor and the organ transplants are registered in the Informative Transplant System as established by the law 91/99. In addition, intention to treat (ITT) survival rates were compared among 4 different groups: (1) patients on standard waiting lists vs (2) patients on urgency waiting lists, and (3) patients with a history of transplant in urgency vs (4) patients with a history of transplant not in urgency. Results. Out of the 370 requests included in the study, 291 (78.7%) were satisfied with liver transplantation. Seventy-nine requests (21.3%) have not been processed, but if we consider only the real failures, this percentage falls to 13.1% and the percentage of satisfied requests rises to 86.9%.
    [Show full text]
  • Spain, France and Italy Are to Exchange Organs for Donation Chains
    Translation of an article published in the Spanish newspaper ABC on 10 October 2012 O.J.D.: 201504 Date: 10/10/2012 E.G.M.: 641000 Section: SOCIETY Pages: 38, 39 ----------------------------------------------------------------------------------------------------------------- This is what happened in Spain’s first ‘crossover’ transplant [For diagram see original article] Altruistic donor The chain started with the kidney donation from a ‘good Samaritan’ going to a recipient in a couple. The wife of the first recipient donated her kidney to a sick person in a second couple. The wife of the second recipient donated her kidney to a third patient on the waiting list. On the waiting list The final recipient, selected using medical criteria, was on the waiting list to receive a kidney from a deceased donor for three years. Spain, France and Italy are to exchange organs for donation chains ► The creation of this type of ‘common area’ in southern Europe will increase the chances of finding a donor match CRISTINA GARRIDO BRUSSELS | Stronger together. Although there are many things on which we find it difficult to agree, this time the strategy was clear. Spain, France and Italy have signed the Southern Europe Transplant Alliance to promote their successful donation and transplant system – which is public, coordinated and directly answerable to the Ministries of Health, as compared to the private models of central and northern Europe – to the international bodies. ‘We (Spain, France and Italy) decided that we had to do something together because we have similar philosophies, ethical criteria and structures and we could not each go our own way given how things are in the northern countries’, explained Dr Rafael Matesanz, Director of the Spanish National Transplant Organisation, at the seminar on donations and transplants organised by the European Commission in Brussels yesterday.
    [Show full text]
  • Value of Donor–Specific Anti–HLA Antibody Monitoring And
    CLINICAL RESEARCH www.jasn.org Value of Donor–Specific Anti–HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss † †‡ | Denis Viglietti,* Alexandre Loupy, Dewi Vernerey,§ Carol Bentlejewski, Clément Gosset,¶ † † †‡ Olivier Aubert, Jean-Paul Duong van Huyen,** Xavier Jouven, Christophe Legendre, † | † Denis Glotz,* Adriana Zeevi, and Carmen Lefaucheur* Departments of *Nephrology and Kidney Transplantation and ¶Pathology, Saint Louis Hospital and Departments of ‡Kidney Transplantation and **Pathology, Necker Hospital, Assistance Publique Hôpitaux de Paris, Paris, France; †Paris Translational Research Center for Organ Transplantation, Institut National de la Santé et de la Recherche Médicale, UMR-S970, Paris, France; §Methodology Unit (EA 3181) CHRU de Besançon, France; and |University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania ABSTRACT The diagnosis system for allograft loss lacks accurate individual risk stratification on the basis of donor– specific anti–HLA antibody (anti-HLA DSA) characterization. We investigated whether systematic moni- toring of DSA with extensive characterization increases performance in predicting kidney allograft loss. This prospective study included 851 kidney recipients transplanted between 2008 and 2010 who were systematically screened for DSA at transplant, 1 and 2 years post-transplant, and the time of post– transplant clinical events. We assessed DSA characteristics and performed systematic allograft biopsies at the time of post–transplant serum evaluation. At transplant, 110 (12.9%) patients had DSAs; post- transplant screening identified 186 (21.9%) DSA-positive patients. Post–transplant DSA monitoring im- proved the prediction of allograft loss when added to a model that included traditional determinants of allograft loss (increase in c statisticfrom0.67;95%confidence interval [95% CI], 0.62 to 0.73 to 0.72; 95% CI, 0.67 to 0.77).
    [Show full text]
  • April 2–6, 2008 Gaylord Texan, Dallas, Texas Spring
    Spring ’08 Clinical Meetings April 2–6, 2008 Gaylord Texan, Dallas, Texas JC A[[fkfm_j^A;;F <_dZekj^emj^[DWj_edWbA_Zd[o<ekdZWj_edÊi A_Zd[o;Whbo;lWbkWj_edFhe]hWcYedj_dk[i je[nfWdZ$$$ @::E^hi]ZaVg\ZhiYZiZXi^dcegd\gVb^ci]Z Jc^iZYHiViZh[dg`^YcZnY^hZVhZ# BdgZi]Vc&%%!%%%eVgi^X^eVcih @::E^h[daadl^c\"jel^i]eVgi^X^eVcihdkZg VcZmiZcYZYeZg^dYd[i^bZ# <adWVaZmeVch^dcd[@::E^hjcYZglVn# B[Whdceh[WXekjA;;F m^_b[oekWh[Wjj^[Yed\[h[dY[$ &# K^hijhVii]ZC@;Wddi],&.[dgi]ZaViZhi^c[dgbVi^dc# '#?d^cjh[dgV[gZZ8B:7gZV`[VhiHnbedh^jb^c<gVeZk^cZ8 dcHVijgYVn!6eg^a*!'%%-[gdb+/%%VbÄ-/%%Vb/ Æ8]gdc^X@^YcZn9^hZVhZ>ciZgkZci^dch/ >begdk^c\8@9VcY8K9DjiXdbZh#Ç (# K^Zli]ZaViZhi@::EYViVWZ^c\egZhZciZY^c&&edhiZgh Yjg^c\i]ZedhiZghZhh^dc#Add`[dgedhiZgcjbWZgh/)*!*(! +)!,*!,,!,-!'%*!',%!'-'!'-(VcY'-.# NdjXVcVahdk^h^ia[[fedb_d[$eh][dgi]ZaViZhi@::E^c[dgbVi^dcVcYVhX]ZYjaZd[ hXgZZc^c\hVXgdhhi]ZJ#H# www.keeponline.org '%%-CVi^dcVa@^YcZn;djcYVi^dc!>cX#6aag^\]ihgZhZgkZY#%'"(*"),(6 Prints: 4C — Live Size: 8"w x 11"h Size:Trim 9"w x 12"h Bleed Size: 9.25"w x 12.25"h Ad PGF-0288 AST Abstracts/American of Journal Transplantaion Mechanical resized from by PGF-0163 CF •C •M •Y •Y •K Your Partner in Transplantation At Astellas, we are committed to uncovering new possibilities in immunology through broad scale research aimed at new product development. Through the transference and sharing of scientifi c knowledge, we work in partnership with healthcare professionals like you to positively impact patient care. Our goal remains clear: Enhance the practice of transplantation.
    [Show full text]
  • 2015 UNOS Transplant Mangement Forum Abstracts
    ABSTRACTS 2015 UNOS Transplant Management Forum, San Diego, CA CATEGORY 1 Cost Reduction/Increase in Work Efficiency/Patient Care Safety Programs ABSTRACT C1-A FEASIBILITY OF REMOTE MONITORING OF VITAL SIGNS AMONG KIDNEY TRANSPLANT RECIPIENTS Stephen Pastan, MD, Emory Transplant Center, Atlanta, GA Purpose: We conducted a pilot study of in-home monitoring in a cohort of renal transplant patients to determine the feasibility of remotely monitoring vital data, and to identify abnormal values that could be intervened upon early to avoid hospital readmissions. The use of in-home "hovering" technologies, which can remotely transmit relevant clinical data, has been associated with decreased readmission rates and reduced costs in other patient populations. However, no study has examined the impact of a hovering platform in post-kidney transplant patients – a population at high-risk for readmissions. Methods: A cohort of adult kidney transplant recipients within 12 months of transplant were identified by transplant center coordinators and providers, and were given the hovering platform equipment during a post-transplant clinic visit. Patients were trained on equipment setup and use by study staff and were instructed to measure blood pressure, pulse oxygen, weight, temperature, and blood sugar levels (if diabetic) for 1 to 3 months. Except for the thermometer and glucometer, devices were connected via blue tooth to a main hub. Vital measurements were transmitted to the hub and automatically downloaded by cell or land-line to a software program that was monitored daily by study staff. In the case of an abnormal reading, study staff notified the patient’s nurse and/or physician, who contacted the patient and intervened as necessary.
    [Show full text]
  • Anhang 1 Eurotransplant International Foundation
    Anhang 1 Eurotransplant International Foundation A m 1. Dezember 1997 trat in der Bundesrepublik Deutschland das Gesetz über die Spende, Entnahme und Übertragung von Organen, kurz Transplantationsgesetz (TPG) genannt, in Kraft. Es regelt neben den Voraussetzungen für eine Organspende auch die Verteilung der verfügbaren vermittlungspflichtigen Or- gane (Herz, Lunge, Leber, Niere, Bauchspeicheldrüse, Dünn- darm). Hierzu führt es in § 12(3) aus, dass die vermittlungs- pflichtigen Organe von einer Vermittlungsstelle nach Regeln, die dem Stand der Erkenntnisse der medizinischen Wissen- schaft entsprechen, insbesondere nach Erfolgsaussicht und Dringlichkeit für geeignete Patienten zu vermitteln sind. Die gemeinnützige Stiftung Eurotransplant Foundation (ET) in Lei- den/Niederlande (www.eurotransplant.nl) wurde vom Gesetz- geber mit der Wahrnehmung der Aufgabe der Vermittlungsstel- le beauftragt. Neben der Vermittlungsstelle sieht der Gesetzgeber im TPG auch die Einrichtung einer Koordinierungsstelle – wahrgenom- men von der Deutschen Stiftung für Organtransplantation (DSO) – zur Koordinierung aller Aspekte der Organsspende vor. ET ist eine 1967 von dem Transfusionsmediziner Jon van Rood ins Leben gerufene Non-Profit-Organisation. Van Rood erkannte die grundlegende Bedeutung des HLA-Systems für die allogene Organtransplantation und regte an, das HLA von Spen- der und Empfänger bei Zuteilung von Organtransplantaten, ins- besondere bei der Nierentransplantation, zu berücksichtigen. Um über einen größeren Pool an Spendern und Empfängern zu verfügen und somit eine optimierte Organzuteilung zu errei- 172 z Anhang 1 Eurotransplant International Foundation chen, wurde ein erster europäischer Transplantationsverbund von den Ländern Belgien, Niederlande, Luxemburg und Deutschland gegründet. Dieser wurde 1971 durch Österreich und im Jahr 2000 durch den Beitritt von Slowenien erweitert. ET ist eine gemeinnützige Stiftung, die von den beteiligten Staaten bzw.
    [Show full text]
  • The History of Kidney Transplantation: Past, Present and Future (With Special References to the Belgian History)
    1 The History of Kidney Transplantation: Past, Present and Future (With special references to the Belgian History) Squifflet Jean-Paul University of Liege Belgium 1. Introduction The history of kidney transplantation is thought to have originated at the early beginning of the previous century with several attempts of Xenografting, and experimental works on vascular sutures (Küss & Bourget, 1992)1. But it really started more than 60 years ago with first attempts of deceased donor transplantation (DCD) and the first successful kidney transplantation of homozygote twins in Boston (Toledo-Pereyra et al, 2008)2. Belgian surgeons contributed to that field of medicine by performing in the early sixties the first ever organ procurement on a brain dead heart beating donor (DBD) (June 1963) (Squifflet, 2003)3. Later on, in the eighties, they published a first series of living unrelated donor (LURD) transplantations, as well as ABO-Incompatible living donor (ABO-Inc LD) transplantations. With the advent of Cyclosporine A, and later other calcineurin inhibitors such as Tacrolimus, with the advent of more potent immunosuppressive drugs (IS), the gap between the number of renal transplant candidates and the number of transplanted recipients was and is continuously increasing in Belgium and most countries. It opened the search for other sources of organs such as donors after cardiac death (DCD) defined with the Maastricht conference and the extended criteria donors (ECD) compared to standard criteria donors (SCD). In Belgium another source of DCD was identified after the promulgation in 2002 of a law on euthanasia. The Belgian example and all its historical measures could help others to fight against organ shortage and its consequences, organ trafficking, commercialization and tourism.
    [Show full text]
  • 39Th Annual Meeting
    Thank you to the 2013 ASHI Corporate Supporters Abbott Molecular Art Robbins Instruments Bio-Rad Laboratories DiaSorin, Inc. Elsevier GenDx Histogenetics Immucor Life Technologies Linkage Biosciences Inc. MLC Group, LLC mTilda HLA Software Specialists National Marrow Donor Program Olerup, Inc. Omixon Biocomputing One Lambda Inc., a part of Thermo Fisher Scientific Inc. STEMCELL Technologies Inc. Final Program 3 Table of Contents General Information .....................................5 ASHI Program Planning Committee. 9 Abstract Reviewers. 10 Board of Directors .....................................13 Corporate Supporters ...................................14 Exhibitor Directory. 15 Award Winners .......................................27 Schedule at a Glance ...................................34 Abstracts ...........................................42 Hotel and Exhibit Floor Plans ..............................95 4 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 General Information Registration Registration is located on the Lobby Level to the left of the main entrance. Sunday, November 17 Noon – 7:30 PM Monday, November 18 7:00 AM – 4:00 PM Tuesday, November 19 7:30 AM – 6:00 PM Wednesday, November 20 8:00 AM – 6:00 PM Thursday, November 21 8:00 AM – 10:30 AM Speaker Ready Room The Speaker Ready Room is located in Parlor D on the Lobby Level, Level 3. Sunday, November 17 5:00 PM – 7:00 PM Monday, November 18 7:00 AM – 4:00 PM Tuesday, November 19 7:00 AM – 4:30 PM Wednesday, November 20 7:00 AM – 4:30 PM
    [Show full text]
  • Eindversie Dissertation an Ravelingien
    FACULTY OF ARTS AND PHILOSOPHY PIG TALES, HUMAN CHIMERAS AND MAN-MADE PUBLIC HEALTH HAZARDS AN ETHICAL ANALYSIS OF XENOTRANSPLANT BENEFITS AND RISKS by AN RAVELINGIEN DISSERTATION SUBMITTED IN FULFILMENT OF THE DEGREE OF DOCTOR OF PHILOSOPHY AT GHENT UNIVERSITY (June, 2006) SUPERVISOR CO-SUPERVISORS Prof. Dr. JOHAN BRAECKMAN Prof. Dr. ILSE KERREMANS Prof. Dr. ERIC MORTIER Prof. Dr. FREDDY MORTIER {Title page: The illustration is an adaptation of the embryo drawings drawn by Ernst Haeckel in 1866 for his Recapitulation Theory} Acknowledgements The process of writing this dissertation has been nothing short of a growing experience. It has allowed for a gradual transition from student life to ‘reality’, while giving me the opportunity to further extend the roots of my education and main interests. I want to thank the Flemish Fund for Scientific Research for the financial support of this research project, which has introduced me to new ideas, new people and new parts of the world. Of course, there would not have been a project had Johan Braeckman not encouraged me to apply for a grant to begin with. Johan has witnessed my ‘growth process’ (as well as the growing pains that have accompanied it) and I am deeply indebted to him for his active belief in my work as well as for the continuous support, encouragement and constructive criticism. It seems that nothing was too much to ask him. Despite his busy schedule, he never resisted reading, rereading and commenting on my papers. His dedication to ethics and philosophy is sincere, inspiring and fun (indeed, what would philosophy be without Cosmo Kramer?).
    [Show full text]
  • Annual Report
    2018 ANNUAL REPORT dkms.de MATHIES BECKER When Mathies was a child, a stem cell transplant saved his life. PAGE 10 > CONTENTS EDITORIAL 4 SPOTLIGHT 2018 More than just a job: We connect people 6 Blood cancer: The figures 9 STORIES Emotional beginnings, tireless research 10 Development of stem cell collections 13 QUALITY AND EFFICIENCY Always on the lookout for the best donor 14 Interview with Professor Thomas Klingebiel: “It’s about finding the best approach” 17 MEDICINE AND RESEARCH In pursuit of a single goal: A cure 18 OUR DONORS Focus on true heroes 22 JOINING FORCES FOR PATIENTS Our motto: Never give up! 28 World Blood Cancer Day 30 GLOBAL COMMITMENT Stem cells for the world 32 HELPERS AND SUPPORTERS Volunteering can save lives 36 FAQs Social media 2018 40 FACTS & FIGURES Financial results 2018 42 About DKMS gGmbH 45 Balance sheet 46 Income statement 48 Risk management 50 Our contributors 52 PUBLICATION DETAILS 53 “We are deeply grateful to everyone who supports our endeavors to reach out to more and more patients with blood cancer. But we still have much more to do. Crucially, we need more young donors.” DR. ELKE NEUJAHR As Chair of the Board of Directors, Elke Neujahr runs DKMS and its various locations in Germany and worldwide. She is convinced that a global network and collaboration with partners are needed to win the fi ght against blood cancer. 4 I ANNUAL REPORT 2018 Dear Reader, In 2018, the desire to support blood cancer patients by providing the life -saving stem cell transplants they need was tremendous again, with more than 600,000 new donors joining our registry in Germany alone.
    [Show full text]